Health
Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients – News-Medical.Net
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large…
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular immunotherapy doesn’t work for every patient.
Moffitt Cancer Center, one of the leading centers for cellular immunotherapy, is researching why some patients…
-
Noosa News16 hours agoSeller disclosure a game changer for Qld – Proctor
-
General19 hours agoAir Canada cancels flights ahead of work stoppage
-
Noosa News19 hours agoResidents want flight curfews and caps as new overhead paths considered for Brisbane Airport
-
General20 hours agoBeijing’s first World Humanoid Robot Games open